Subcutaneous vs. IV Administration of Rituximab in Follicular Lymphoma

Share this content:

the Cancer Therapy Advisor take:

In a new study published in the Journal of Clinical Oncology, researchers were able to determine a rituximab dose that, when administered subcutaneously, would induce the same rituxmimab serum trough concentration (Ctrough) as when the treatment is administered intravenously (IV). Specifically, they found that a fixed dose of 1,400 mg yielded Ctrough levels that were noninferior to those observed with a 375-mg/m2 IV dose. This was confirmed for 2- and 3-month regimens, according to study results. Safety profiles were similar, with 79% of patients experiencing at least one adverse event in each group. Mild to moderate administration-related were more common after subcutaneous administration. While encouraging, the researchers noted that further study is needed to ensure that efficacy of subcutaneous rituximab is also noninferior to IV rituximab.

For Lymphoma Patients Receiving R-CHOP, Entecavir More Effective for HBV-Related Hepatitis Prophylax
Subcutaneous vs. IV Administration of Rituximab in Follicular Lymphoma

The fixed dose of 1,400 mg subcutaneous (SC) rituximab predicted by using stage 1 results was confirmed to have noninferior Ctrough levels relative to IV rituximab 375 mg/m2 dosing during maintenance, with a comparable safety profile in patients with follicular lymphoma. Additional investigation will be required to determine whether the SC route of administration for rituximab provides equivalent efficacy compared with that of IV administration.

READ FULL ARTICLE From Ascopubs

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs